Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.

[1]  Michel Sadelain,et al.  The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.

[2]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[3]  Sylvain Julien,et al.  Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1 , 2008, The Journal of Immunology.

[4]  M. Sadelain,et al.  T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection , 2007, Nature Medicine.

[5]  C. June,et al.  4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.

[6]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[7]  S. Riddell,et al.  Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. , 2007, Human gene therapy.

[8]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[9]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[10]  M. Brenner,et al.  Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.

[11]  M. Sadelain,et al.  269. Integrated CD28 and 4-1BB Signals Strongly Potentiate CD8+ T Cell Mediated radication of Metastatic Prostate Cancer , 2006 .

[12]  Michel Sadelain,et al.  Targeted elimination of prostate cancer by genetically directed human T lymphocytes. , 2005, Cancer research.

[13]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Vallejo,et al.  CD28 extinction in human T cells: altered functions and the program of T‐cell senescence , 2005, Immunological reviews.

[15]  S. Rosenberg,et al.  Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. , 2005, The Journal of clinical investigation.

[16]  Xianglin Shi,et al.  ILK mediates actin filament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling , 2005, Oncogene.

[17]  B. Dörken,et al.  Costimulation by CD137/4–1BB inhibits T cell apoptosis and induces Bcl‐xL and c‐FLIPshort via phosphatidylinositol 3‐kinase and AKT/protein kinase B , 2005, European journal of immunology.

[18]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[19]  C. June,et al.  The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. , 2005, Blood.

[20]  M. Smyth,et al.  Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. , 2004, Human gene therapy.

[21]  D. Fruman.  Phosphoinositide 3-kinase and its targets in B-cell and T-cell signaling. , 2004, Current opinion in immunology.

[22]  J. Trapani,et al.  A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells , 2004, Cancer Gene Therapy.

[23]  G. Mufti,et al.  Role of 4-1BB:4-1BB ligand in cancer immunotherapy , 2004, Cancer Gene Therapy.

[24]  Oreste Acuto,et al.  CD28-mediated co-stimulation: a quantitative support for TCR signalling , 2003, Nature Reviews Immunology.

[25]  M. Croft.  Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? , 2003, Nature Reviews Immunology.

[26]  A. Weiss,et al.  The PI‐3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3 , 2003, Immunological reviews.

[27]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[28]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[29]  J. Trapani,et al.  Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. , 2002, Blood.

[30]  M. Debenedette,et al.  4-1BB Ligand Induces Cell Division, Sustains Survival, and Enhances Effector Function of CD4 and CD8 T Cells with Similar Efficacy1 , 2001, The Journal of Immunology.

[31]  E. Bertram,et al.  4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors. , 2001, Cellular immunology.

[32]  A. Shaw,et al.  Cutting Edge: Distinct Motifs Within CD28 Regulate T Cell Proliferation and Induction of Bcl-XL1 , 2001, The Journal of Immunology.

[33]  D. Sargent,et al.  Enhanced Therapeutic Potential of Adoptive Immunotherapy by In Vitro CD28/4-1BB Costimulation of Tumor-Reactive T Cells Against a Poorly Immunogenic, Major Histocompatibility Complex Class I-Negative A9P Melanoma , 2000, Journal of immunotherapy.

[34]  Michael J. Parsons,et al.  Protein Kinase B Regulates T Lymphocyte Survival, Nuclear Factor κb Activation, and Bcl-XL Levels in Vivo , 2000, The Journal of experimental medicine.

[35]  Michel Sadelain,et al.  Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells , 2000, Nature Biotechnology.

[36]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[37]  R. Ahmed,et al.  4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses. , 1999, Journal of immunology.

[38]  N. Bander,et al.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. , 1999, Neoplasia.

[39]  M. Debenedette,et al.  4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. , 1999, Journal of immunology.

[40]  T. Mak,et al.  CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand , 1998, The Journal of experimental medicine.

[41]  L. Zitvogel,et al.  Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. , 1998, Cancer gene therapy.

[42]  Lieping Chen,et al.  Amplification of tumor immunity by gene transfer of the co‐stimulatory 4‐1BB ligand: synergy with the CD28 co‐stimulatory pathway , 1998, European journal of immunology.

[43]  D. Pardoll,et al.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  B. Hemmings,et al.  Ligation of the T cell co‐stimulatory receptor CD28 activates the serine‐threonine protein kinase protein kinase B , 1997, European journal of immunology.

[45]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[46]  B. Kwon,et al.  Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. , 1997, Journal of immunology.

[47]  C. Thompson,et al.  CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. , 1995, Immunity.

[48]  R. Schwartz.  T cell anergy. , 2003, Annual review of immunology.

[49]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.